News

RIVANNA announces award from U.S. government to develop Accuro Platform for rapid triage of blast-related injuries

RIVANNA®, developers of imaging-based medical solutions, announced that they have received a contract from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the design and development of a computer-aided 3D fracture detection and diagnosis product, called Accuro® XV. Under the contract 75A50121C00035, HHS/ASPR/BARDA will provide $11.6 million over 24 months with options for additional funding for supporting further development up to $65 million.

The project’s overarching objective is to achieve a market-ready, clinically proven and FDA-cleared Accuro XV product for rapid, radiation-free fracture detection and aid triage in emergency medicine; a critical medical countermeasure to ensure timely triage for reduction of morbidity and mortality in mass-casualty blast trauma incidents, for which, no field-deployable equipment for extremity fractures currently exists.

The Accuro XV is a portable medical system building on novel technologies that underpin RIVANNA’s extensive patent portfolio, including BoneEnhance® Multi-Frequency Image Reconstruction, which optimizes ultrasound for the visualization of bony versus soft-tissue anatomy. Supporting this image reconstruction technology is Multi-Probe Multi-Angle BoneVision™, an automated image-acquisition technique based on a series of novel three-dimensional ultrasound-based bone-imaging technologies that increases angular image sensitivity to bone surfaces. BoneVision provides precisely captured bony anatomical structures within a large field of view and demonstrated performance detecting small fractures with high sensitivity and specificity.

By automating both the image acquisition and image interpretation, Accuro XV will also support just-in-time training, ideal for mass-casualty incidents; the ease of use afforded by the automation will reduce user dependence and optimize the success of clinical evaluations for adoption in hospital and emergency room (ER) settings.

Will Mauldin, PhD, co-founder, and CEO of RIVANNA, commented, “We are pleased to receive this award from BARDA. With attainment of targeted product performance specifications, the clinical and economic value of Accuro XV is expected to result in an inevitable shift away from the current state of X-ray overutilization towards a radiation-free, bedside triage standard of care.”

 

To learn more please visit RIVANNA

Recent News

04/24/2025

SSI Diagnostica Group Acquires Breath Test Maker Gulf Coast Scientific

Infectious disease diagnostics firm SSI Diagnostica Group said on Thursday that it has acquired Florida-based breath testing firm Gulf Coast Scientific for an undisclosed sum. Gulf Coast Scientific is a developer of urea breath tests for Helicobacter pylori infection, which is associated with conditions including chronic gastritis and gastric cancer. SSID Group said that the

04/23/2025

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories

04/22/2025

Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in America

Phlow Corp., a leading pharmaceutical contract development and manufacturing organization (CDMO) in America, announced a significant expansion in its analytical capabilities, use of artificial intelligence (AI), workforce, and domestic infrastructure. Marking a period of exceptional growth and momentum, Phlow has more than doubled in size and now employs over 90+ highly skilled scientists and professionals